GlassScriptPhysician profile
Yasmin Sabet
NPI 1215349428
$4,575.45
in general payments reported to CMS, 2019-2025
21 companies · $723 in 2025
The $723 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $723 · 2021: $1,160 · 2022: $291 · 2023: $815 · 2024: $682 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $899.20 | 2022-2025 | Saphnelo |
| Abbvie INC. | $811.65 | 2019-2025 | Rinvoq |
| Ucb, INC. | $786.86 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $500.29 | 2019-2025 | Evenity, Prolia |
| Janssen Biotech, INC. | $235.48 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.48 | 2020-2025 | Jardiance, Ofev, Cyltezo |
| Lilly USA, LLC | $174.95 | 2020-2021 | |
| Glaxosmithkline, LLC. | $151.44 | 2020-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $123.43 | 2020-2021 | |
| Radius Health, INC. | $106.23 | 2020-2022 | |
| Pfizer INC. | $89.28 | 2019-2023 | |
| Horizon Therapeutics Plc | $76.94 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $71.07 | 2022-2023 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $68.84 | 2023 | Inspire |
| Aurinia Pharma U.S., INC. | $66.06 | 2022-2023 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $58.35 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $38.19 | 2020 | |
| Organon LLC | $25.49 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $23.32 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Sabet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.